Alzamend Neuro Inc SEC Filings

Alzamend Neuro filed Certificates of Elimination with the Delaware Secretary of State for its Series B and Series C convertible preferred stock. The filings, effective upon submission on October 14, 2025, remove from the company’s amended Certificate of Incorporation the matters set forth in the Certificates of Designations for these preferred series.

Copies of the Certificates of Elimination are included as Exhibits 3.1 (Series B) and 3.2 (Series C).

Milton C. Ault III, a director of Alzamend Neuro, Inc. (ALZN), reported a series of transactions in early October 2025. On 10/08/2025 he converted Series B convertible preferred shares into 61,743 shares of common stock at a conversion price of $2.32, increasing the indirect holdings reported for Ault Lending, LLC to 130,591 shares. That same day he sold 101,394 shares in open-market transactions at a volume-weighted average price of $2.4376 (trade range $2.42–$2.4634).

On 10/09/2025 he sold an additional 20,397 shares at $2.3234, leaving Ault Lending, LLC with 8,260 indirectly held shares. The filing also shows other indirect holdings: 11,068 shares via Ault Life Sciences, Inc. and 61 shares via Ault Life Sciences Fund, LLC, plus several warrants totaling 23,334 underlying common shares across three warrant issuances.

Milton C. Ault III, a director of Alzamend Neuro, Inc. (ALZN), reported multiple insider transactions in October 2025. He converted Series B preferred shares into 100,000 common shares on 10/03/2025 and again on 10/07/2025, and sold portions of common stock in open-market transactions: 82,033 shares on 10/06/2025 at a VWAP of $2.4535 and 57,379 shares on 10/07/2025 at a VWAP of $2.4914. After these moves, beneficial ownership is reported indirectly through entities including Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC. The filings disclose outstanding warrants and converted preferred stock that underlie additional common shares.

Alzamend Neuro, Inc. holders led by Milton C. Ault III report combined beneficial ownership of 166,909 shares, representing approximately 4.4% of the company's 3,739,861 outstanding shares as of October 7, 2025. The filing aggregates direct holdings, shares underlying Series B convertible preferred stock and exercisable warrants, and stock options across related entities including Hyperscale Data, Ault Lending, Ault Life Sciences and others.

The statement breaks out voting and dispositive power: Mr. Ault holds 1,843 shares directly and shared voting power over 165,066 shares; Hyperscale Data and Ault Lending each report beneficial ownership of roughly 153,937 and 153,925 shares respectively (about 4.0%). Purchase prices for several block holdings are disclosed in aggregate dollar amounts, and no transactions in the past 60 days are reported except as listed in an exhibit.

Alzamend Neuro (ALZN) filed Amendment No. 10 to Schedule 13D, updating beneficial ownership by Milton C. Ault III and affiliated entities. The filing is based on 3,539,861 shares outstanding as of October 2, 2025.

Mr. Ault may be deemed to beneficially own 306,321 shares, or approximately 8.0% of the class, including direct holdings and shares attributable through affiliates. Hyperscale Data, Inc. reports 293,349 shares (approximately 7.7%), and Ault Lending, LLC reports 293,337 shares (approximately 7.7%). These positions include 261,743 shares underlying Series B Convertible Preferred Stock and 23,334 shares underlying currently exercisable warrants held by Ault Lending, plus smaller direct common holdings across affiliates.

The filing details voting and dispositive powers across entities and notes that no transactions in the past 60 days occurred other than those listed in an exhibit.

Milton C. Ault III, a director of Alzamend Neuro, Inc. (ALZN), reported multiple transactions in early October 2025. On 10/01/2025 he converted Series B convertible preferred shares into 100,000 shares of common stock at a conversion price of $2.32. On 10/01–10/03/2025 he sold common shares in open-market transactions: 36,777 shares on 10/01 at a VWAP of $2.3487, 20,686 shares on 10/02 at $2.394, and 65,903 shares on 10/03 at a VWAP of $2.4413, totaling 123,366 shares sold.

The Form 4 lists changing beneficial ownership figures tied to Ault-controlled entities: following the conversion Ault Lending is reported with 131,626 shares beneficially owned, which moved to 94,849, then 74,163, and then 8,260 after the sales. Additional holdings are shown for Ault Life Sciences, Inc. (11,068) and Ault Life Sciences Fund, LLC (61), with voting and investment power described in the filing.

Alzamend Neuro, Inc. (ALZN) Schedule 13D/A discloses that Milton C. Ault, III and affiliated entities beneficially own a combined 429,687 common shares, representing approximately 11.2% of the 3,439,861 shares outstanding reported by the issuer. That total includes direct holdings, stock options, warrants and shares underlying Series B convertible preferred stock held across Hyperscale Data, Ault Lending, Ault Life Sciences and related entities.

The filing breaks out ownership and voting/dispositive power: Mr. Ault directly holds 1,843 shares and shares control of 427,844 shares; Hyperscale Data and Ault Lending each report approximately 10.9% beneficial ownership. The filing states sources of funds for purchases (working capital or personal funds) and lists aggregate purchase prices for several holdings and instruments. No transactions in the past 60 days are reported except as set forth in Exhibit 1.

Milton C. Ault III, identified as a director and a 10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple sales of the company’s common stock in late September 2025. The filings show sales on 09/26/2025 of 37,738 shares at $2.3145, on 09/29/2025 of 38,324 shares at $2.309, and on 09/30/2025 of 3,566 shares at $2.3334. After those transactions, beneficial ownership reported for the related entities was 73,516 shares (indirect) by Ault Lending, LLC, 35,192 shares (indirect) by Ault Lending, LLC, and 31,626 shares (indirect) by Ault Lending, LLC, respectively. Additional holdings include 11,068 shares held indirectly by Ault Life Sciences, Inc. and 61 shares indirectly by Ault Life Sciences Fund, LLC. The Form 4 is signed by Mr. Ault on 09/30/2025.